Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices. Outside of the pharmaceutical field, Andrew’s practice encompasses agrochemicals, polymer chemistry, petroleum additives, catalytic compositions, separation chemistry, adhesive technologies and biosensors.
Andrew acts for a diverse range of clients, including international corporations, universities, start-up companies and associate patent attorney firms based outside of the UK.
He commenced his patent career in private practice before joining the in-house patent department of a major multi-national pharmaceutical company in June 2004. As an in-house attorney, Andrew was responsible for the patent portfolios relating to a number of high priority drug development projects, as well as conducting IP due diligence evaluations to support in-licensing activities. Andrew returned to private practice in November 2008 when he joined the Manchester office of HGF as a Partner.
Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.
The development and evaluation of microparticulate formulations for DNA immunisation
Postgraduate Certificate in Intellectual Property Law
Andrew is listed in the IAM Strategy 300 as a leading IP strategist
Andrew is listed in the IAM Patent 1000 as a leading IP attorney in his field.
Andrew is listed as a MIP Star.
Andrew mentors and contributes to the professional training of Trainee Patent Attorneys within HGF, as well as mentoring and training of IP and technology transfer professionals in other organisations.
The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’. Such a refusal can …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.